Second, further in vitro experiments were needed to better understand the shared mechanism of PC and T2DM “regulation of endodermal cell fate specification.” At last, there is not enough evidence that S100A6 is a good predictor for T2DM and PC patients, and it still needs to be verified in future clinical trials. Here, S100A6 is linked to pachyonychia congenita.